Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications

1.25 CME
$0 FEE
Cytomegalovirus in the Transplantation Setting: Assessing the Evidence in Real-world Applications


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by an educational grant from Merck & Co., Inc.

Activity Description

Cytomegalovirus (CMV) infection after solid organ and hematopoietic stem cell transplantation is one of the most critical infectious complications related to host immune recovery. Management of CMV is categorized into prophylaxis, preemptive, and targeted treatment. Conventional anti-CMV therapies are associated with suboptimal efficacy, toxicities, and resistance. Newer antivirals may provide effective prevention as well as treatment of CMV disease without the safety concerns and drug resistance. In this continuing medical education activity, expert clinicians will discuss the latest on diagnosing and managing patients with CMV infection in the transplantation setting.

Target Audience

The intended audience for the activities is infectious disease specialists and other health care professionals involved in the management of patients with cytomegalovirus.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Incorporate recent evidence into practice regarding the use of prophylactic and preemptive measures to prevent CMV disease in transplant recipients.
  • Differentiate conventional versus newer antiviral therapies in terms of safety and efficacy, ability to reduce CMV reactivation, and improvement in survival of transplant recipients.
  • Evaluate the optimal duration of prophylactic or preemptive treatment in patients at risk for CMV reactivation.

Activity Chair

Francisco M. Marty, MD, FIDSA
Associate Professor of Medicine
Harvard Medical School
Associate Physician, Brigham and Women's Hospital
Staff Physician, Dana-Farber Cancer Institute
Boston, MA


Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases, Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX

Genovefa A. Papanicolaou, MD, FIDSA
Attending Physician, Director of Clinical Trials, Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
New York, NY


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, November 24, 2020, through November 23, 2021.

How To Participate in This Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the poll and pretest questions, view the content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers, and staff involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.

Activity Chair and Faculty report the following relationship(s)

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Consulting Fee: Ansun BioPharma, Chimerix, Cidara, Janssen, Merck, Oxford Immunotec, ReViral, Takeda
Speakers Bureau: Merck
Contracted Research: AiCuris, Ansun BioPharma, Janssen, Karius, Merck, Takeda, Viracor

Francisco M. Marty, MD, FIDSA
Consulting Fee: AlloVir, Amplyx, Avir, Janssen, Kyorin, Merck, Regeneron, ReViral, Symbio, United Medical
Contracted Research: Amplyx, Ansun, Chimerix, Cidara, F2G, Gilead, Merck, Regeneron, Scynexis, Takeda, WHISCON

Genovefa A. Papanicolaou, MD, FIDSA
Consulting Fee: ADMA Biologics, Cidara, Octapharma, Partners Therapeutics, Shionogi, Siemens
Contracted Research: Astellas, Merck, Shire/Takeda
Data Safety Monitoring Committee: Amplyx
Adjudication Committee: Endpoint, Octapharma

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at